Enhancing Recovery after Radical Prostatectomy
At Levee Medical®, we are committed to designing solutions that aim to reduce complications associated with surgical treatment.
One in 8 men will develop prostate cancer*
Patients often choose surgery to treat prostate cancer
In most cases, surgery enables complete and immediate removal of cancer.
Urinary incontinence after prostatectomy remains a debilitating problem
It is the most feared complication following surgery for prostate cancer.
Life after prostatectomy deserves to be brilliant
Our goal is to minimize incontinence so that patients can turn the page after prostate cancer surgery.
Introducing
Voro® Urologic Scaffold
Transforming prostatectomy recovery with the first and only absorbable device specifically engineered to address urinary incontinence head-on.
Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence following Radical Prostatectomy: A Report of 2 Cases, Urologia Internationalis
The Levee Medical Voro prostatectomy implant is not approved for sale worldwide. It is not FDA-cleared or approved. It is currently in the research and development phase and is not available for sale in any country.
Content is intended for healthcare professionals.
Team
Bruce Choi
Founder, Director, CTO & Chairman
Adam Irving
CEO & Director
Kevin Hopkins
Vice President, Quality
Karen Cornett
Vice President, Clinical Affairs
Sean Collins
Vice President,
Market Development
Mike McKellar
Corporate Controller
Mike Henson
Director
Gary McCord
Director
Peter Mulrooney
Director
News
Levee Medical® to Accelerate Development of its Voro® Urologic Scaffold, Designed to Improve Post-Prostatectomy Recovery Outcomes
Additionally, Company Reaches Significant Enrollment Milestones in Feasibility and Observational Studies
Durham, NC – June 10, 2024 – Levee Medical®, a medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has received significant funding commitments to support ongoing regulatory and clinical activities. The funds raised will be instrumental in advancing the development of the Voro® Urologic Scaffold and supporting broader clinical studies to further establish its safety and efficacy.
Levee Medical Secures $4.3M Strategic Investment to Accelerate Clinical Development of the Voro Urologic Scaffold, Designed to Improve Robotic Prostatectomy Outcomes
Milestone Achieved as Company Announces Successful Enrollment of First Patients in its First-in-Human (FIH) Study
DURHAM, NC – Sept. 6, 2023 – Levee Medical, a clinical-stage medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has raised a total of $4.3 million in oversubscribed funds. Additionally, Levee Medical successfully treated the first study participants in its first-in-human (FIH) study, demonstrating initial safety data for the Voro Urologic Scaffold.
Levee Medical™ Announces the Closing of $6.6m Series A Financing
Company to Accelerate Development of Novel Urologic Device Designed to Improve Recovery Outcomes Post-Prostatectomy
Durham, NC – August 23, 2022 – Levee Medical, a medical device company designing solutions to improve surgical outcomes following prostate cancer, announced today it has closed an initial oversubscribed series A financing round, raising a total of $6.6 million. The funds will be used to advance product development, scale infrastructure, and expand the team to support the development of the company’s Voro Urologic Scaffold, a bioresorbable post-prostatectomy implant.